Logo of Quantum Biopharma. Click to go to a Home page

LUCID-MS

Idea/Target Lead In vivo PoC IND Enabling Studies Phase 1 Phase 2 Phase 3 Launch
LUCID-MS
Icon of a head representing LUCID-MSMultiple sclerosis
 Phase-1 in human trials completed

LUCID-MS

Patented new chemical entity (NCE)

Lucid-MS is a patented neuroprotective compound that has demonstrated in preclinical models to prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions. Lucid-MS has shown excellent results in several animal models, as demonstrated in the video below.

LUCID-MS: Disease Modifying Enabling Remyelination

The subject in the video above is only one example taken from a large cohort of mice in experiments conducted in multiple labs across several years. The results of the preclinical research from these experiments has been published in various prestigous medical journals, including Journal of Medicinal Chemistry and Proceedings of the National Academy of Sciences (PNAS). Lucid-MS is a patented (patent #WO2017027967A1) New Chemical Entity (NCE) that has been studied extensively throughout more than 11 years of research and development. Quantum BioPharma owns exclusive worldwide rights to Lucid-MS.

Quantum BioPharma Dr. Andrzej Chruscinski On Recent Multiple Sclerosis Trial Breakthroughs

Dr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma

A sampling of the novel qualities of Lucid-MS include:

A blue check mark on a white background.

Excellent efficacy in various preclinical animal models
A blue check mark on a white background.

Accelerates functional recovery of mouse models of Multiple Sclerosis, preserves myelin, and reduces zonal degradation
A blue check mark on a white background.

Does not suppress immune system (non-immunomodulatory)
A blue check mark on a white background.

Potential oral administration with easy dosing regimen

Quantum BioPharma has completed the dosing of healthy human volunteers for phase-1 clinical trials for Lucid-MS.

Today there is no cure for Multiple Sclerosis.

Quantum BioPharma (“QNTM”) is trying to change this for millions of people.

Multiple Sclerosis Overview

Estimated Diagnosed MS Patients by Region

Image showing a pie chart of current treatment market

A chronic inflammatory and degenerative disorder of the Central Nervous System Global prevalence of MS rose from 2.3 million in 2013 to 2.8 million in 2020


MS is characterized by unpredictable symptoms (i.e. tingling sensations, vision problems, mobility issues) that are attributed to the patient’s immune system attacking different nerve fibers


Damage to myelin (the sheaths protecting nerve fibers) can affect critical thinking and cognitive skills


Global MS treatment market in 2022 estimated at US$23 billion


MS can occur at any age, but the average age for diagnosis globally is 32 years 1.5% of the global MS population is under the age of 18 years


Female to male diagnosis ratio is 2:1


Prevalence in U.S. is 288 cases per 100,000 people; in Canada it is 250 cases per 100,000 people

Armed with a strong balance sheet, solid pipeline, and renowned clinical team, Quantum BioPharma intends to advance its lead drug candidate through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative conditions such as Multiple Sclerosis. We want to see Lucid-MS help those with these conditions, as we advance science, and save lives.

A line drawing of a hand holding a plant with leaves.

Today there is no cure for Multiple Sclerosis (MS). Quantum BioPharma will attempt to change that for millions of suffering people. Quantum BioPharma’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models

A black and white drawing of two hands holding a brain.

Well positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the innovative biotech space focused on “Total Brain Health”

A group of people standing next to each other on a white background.

Renowned clinical team led by Dr. Lakshmi P. Kotra, who is the recipient of the Julia Levy Award, is a Senior Scientist at Krembil Brain Institute, as well as University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of Quantum BioPharma’s wholly owned subsidiary, Lucid Psycheceuticals

Learn about Multiple Sclerosis facts

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) that affects the brain and spinal cord. It is characterized by inflammation, demyelination and degeneration of the CNS. MS progresses in various stages, and the clinical course can vary widely among individuals.

Share by: